RNA therapeutics companies develop medicines that use RNA molecules to alter protein production, silence disease-associated genes or deliver therapeutic instructions to cells. These approaches support the treatment of genetic disorders, cancer, infectious disease and other conditions.
This category includes companies working on:
Browse 62 UK RNA therapeutics companies below.
Non-viral intracellular delivery platform based on biomolecular condensates
PartitionBio is a biotechnology company developing a non-viral intracellular delivery platform based on liquid-liquid phase separation and biomolecular condensates. Its lead product, BubbleFect, is a room-temperature-stable, non-lipid reagent designed for bench-top use without specialist equipment or cold-chain…
Surface acoustic wave nebuliser platform for inhaled drug delivery
Nebu~Flow is a UK medical technology company developing next-generation nebuliser devices using patented surface acoustic wave technology to aerosolise drugs into precisely controlled droplet sizes for deep lung deposition. The platform is designed to enable inhalation delivery of biologics, RNA-based formulations,…
Xeno nucleic acid binders for targeted drug delivery
Xterna is a biotechnology company developing cell-specific molecular binders composed of xeno nucleic acids (XNAs), chemically modified nucleic acids distinct from naturally occurring DNA and RNA. XNA-based binders are engineered to target cell types that evade conventional antibody-based approaches, enabling drug…
Engineered cell-derived vesicles for targeted RNA and drug delivery
AAB Therapeutics develops programmable nanovesicles from engineered human cell membranes for targeted intracellular drug delivery. The vesicles are designed to carry RNA, small molecules or biologics, using surface targeting molecules and fusogenic proteins to release their cargo into cells. The preclinical company…
Preclinical RNA medicines for chronic liver disease and fibrosis
Afortiori Bio is a preclinical biotechnology company developing RNA medicines for chronic liver disease, particularly liver fibrosis. Its lead programme uses Target Site Blocker RNA technology to selectively modulate gene expression in liver cells. The approach is intended to address processes contributing to fibrotic…
Preclinical mRNA nanoparticle therapeutics for chronic inflammatory disease
EVolution Therapeutics is a preclinical-stage biotechnology company developing mRNA nanoparticle and hydrogel-based therapeutics to resolve chronic inflammation and support tissue repair. Spun out of Aston University, its platform delivers mRNA encoding pro-resolving proteins directly to sites of disease. The lead…
Fermentation-derived aquatic parasite control and microalgal delivery technology
Sundew is a blue biotechnology company developing fermentation-derived products to control aquatic parasites and other ecosystem challenges. Its Biokos extract, produced from a naturally occurring marine microorganism, targets protozoan fish parasites including Ich and Cryptocaryon. Sundew is also developing…
Programmable gene control platform for advanced cell therapies
Laverock Therapeutics is a biotechnology company developing a programmable gene control platform for the creation of disease-responsive advanced therapies. The platform uses recoded microRNAs to deliver tunable, stable and multiplexed gene silencing within cell therapies, enabling enhanced precision and improved…
Tissue-targeted gene and RNA delivery platforms for rare and neurological disease
Dawn Therapeutics is a pre-clinical biotechnology company developing precision delivery platforms for genetic medicines targeting the central nervous system, cartilage, and bone. Its transferrin receptor-guided system is designed to cross the blood-brain barrier and deliver RNA or DNA payloads to neuronal tissues,…
Oligonucleotide therapeutics designed to upregulate protein expression
Orfonyx Bio is a biotechnology company developing genetic medicines that increase, rather than silence, the expression of therapeutic target proteins. Its platform generates antisense oligonucleotide modulators that act on regulatory elements within the untranslated regions of genes, inhibiting sequence motifs that…
Cell-specific mRNA delivery platform for genetic medicines
Nuntius Therapeutics is a London-based biotechnology company developing mRNA therapies using proprietary peptide dendrimer and lipid-based nanocarriers designed to deliver genetic payloads to tissues and cell types beyond the liver. The platform combines machine learning-guided carrier design with engineered mRNA…
Modular automated RNA manufacturing platform
Centillion is a UK biotech company whose platform integrates synthesis, purification, and formulation stages using continuous flow chemistry to produce mRNA and self-amplifying RNA at research and production scale. The platform supports process development through to regulatory-ready CMC packages and is available as a…
AI-guided personalised mRNA cancer vaccine development
Genevation is a biotechnology company developing personalised mRNA cancer vaccines using AI-assisted tumour neoantigen identification. Its platform analyses tumour sequencing data to select patient-specific targets and combines computational vaccine design with cell-free RNA manufacturing. The company reports…
Next-generation lipid nanoparticle platform for RNA vaccines and medicines
NeoVac is a biotechnology company developing a next-generation lipid nanoparticle platform to improve the delivery of RNA vaccines and therapeutics. Its library of fully biodegradable, tissue-targeted LNPs addresses limitations of first-generation formulations, offering enhanced thermostability, multiple routes of…
RNA therapeutics targeting cellular senescence and age-related disease
Senisca is a preclinical-stage biotechnology company developing oligonucleotide and small molecule therapeutics that reverse cellular senescence by restoring RNA splicing factor activity. Its platform targets the molecular mechanisms of cellular ageing and has broad applicability across multiple age-related diseases.…
Genomics platform developing RNA therapies for chronic liver disease
Ochre Bio is a biotechnology company developing RNA therapeutics for chronic liver disease using a platform built on large-scale human liver datasets. The platform integrates gene perturbation atlases, single-cell genomics from perfused donor livers, and machine learning to identify and validate disease-modifying drug…
National innovation centre accelerating drug discovery
Medicines Discovery Catapult (MDC) is an independent, not-for-profit national innovation centre that supports UK medicines discovery organisations across the full drug discovery pipeline. MDC provides access to specialist laboratory technologies, computational and AI-driven tools, translational R&D expertise, and…
Optimised mRNA sequence design and therapeutic development software
Jantomarna Therapeutics is a biotechnology company providing computational design technology for protein-coding RNA therapeutics. Its proprietary genetic algorithm optimises mRNA and related RNA sequences for efficacy, safety and manufacturability using mechanistic sequence-function models. The company offers contract…
MicroRNA therapeutics for tendon and musculoskeletal disease
Causeway Therapeutics is a clinical-stage biotechnology company developing first-in-class microRNA therapies for musculoskeletal and age-related conditions. Its lead asset TenoMiR (CWT-001) is a synthetic miR-29a mimic delivered by single intratendinous injection that promotes collagen remodelling and tendon repair.…
Custom modified oligonucleotides for research and therapeutics
ATDBio is a University of Southampton spin-out specialising in custom DNA and RNA oligonucleotide synthesis for research, diagnostics and therapeutic development. Its Southampton-based operations supply standard and chemically modified oligos, including antisense sequences, siRNA, aptamers and labelled probes, using…